Febrile neutropenia is a common complication in cancer patients and has been studied for more than 30 years. This is a field of cancer in which much progress in supportive care has been made, significantly reducing the morbidity and mortality from infections. Tremendous numbers of patients have already benefited from specific antineoplastic therapy and an even greater number could benefit from the prevention of infection or from the allevation of symptoms as a result of effective prophylaxis or adequate therapeutic strategies. This book evaluates the achievements in the past and identifies the…mehr
Febrile neutropenia is a common complication in cancer patients and has been studied for more than 30 years. This is a field of cancer in which much progress in supportive care has been made, significantly reducing the morbidity and mortality from infections. Tremendous numbers of patients have already benefited from specific antineoplastic therapy and an even greater number could benefit from the prevention of infection or from the allevation of symptoms as a result of effective prophylaxis or adequate therapeutic strategies. This book evaluates the achievements in the past and identifies the major existing problems. It gives an overview of therapeutic possibilities and presents new concepts and strategies for making further progress.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
High-Dose Chemotherapy: Safer and Better?.- Bone Marow Protectors in Cancer Treatment.- Hematopoietic growth factors in febrile neutropenia - Indications and limitations.- Incorporation of Quality-of-Life Considerations into Decisions Model for the Use of Colony-Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia.- Assessing Risk in Cancer Patients with Fever and Neutropenia.- Therapeutic Approach in the Ambulatory Setting, Feasability and Surveillance.- The Sequence of Infective Events in Prolonged Neutropenia.- The Empirical Therapeutic Cascade: When to Start and When to Stop?.- Treatment of Neutropenic Infection: Trends Towards Monotherapy?.- The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients.- Susceptibility of Streptococci Isolated from Blood of Neutropenic Patients to 11 Antibiotics.- Emerging Antibiotic Resistance in bacterial Pathogens.- Cefepime Versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients.- Cefepime Versus Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children with Malignancy.- Cefepime-Vancomycin Versus Ceftazidime-Vancomycin as Empiric Therapy in Febrile Neutropenic Patients.- Monotherapy with Meropenem Versus Combination Therapy with Ceftazidime Plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer.- Piperacillin plus Tazobactam Versus Ceftazidime plus Amikacin in Febrile Neutropenia: A Comparison in Terms of Cost and Efficacy.- Fungal Infection in Neutropenic Patients: Past Achivements and Future Problems.- The Pressure of Emerging Resistance in Fungal Diseases.- Liposomal Versus Conventional Amphotericin B for the Treatment of Fever of Unknown Origin in Neutropenic Patients: Results of two Randomized Trials in 204 Childrenand 134 Adults.- Pulmonary Infiltrate Etiology in Leukemic Patients with Fever.- Marrow Transplantation: Current Results and Effect of Immunoglobulin Prophylaxis.- The Role of Economic Evaluation in Assessing the Cost of Febrile Neutropenia.- Quality of life in Patients with Febrile Neutropenia.
High-Dose Chemotherapy: Safer and Better?.- Bone Marow Protectors in Cancer Treatment.- Hematopoietic growth factors in febrile neutropenia - Indications and limitations.- Incorporation of Quality-of-Life Considerations into Decisions Model for the Use of Colony-Stimulating Factors in Chemotherapy Patients at Risk for Febrile Neutropenia.- Assessing Risk in Cancer Patients with Fever and Neutropenia.- Therapeutic Approach in the Ambulatory Setting, Feasability and Surveillance.- The Sequence of Infective Events in Prolonged Neutropenia.- The Empirical Therapeutic Cascade: When to Start and When to Stop?.- Treatment of Neutropenic Infection: Trends Towards Monotherapy?.- The Changing Spectrum of Bacterial Infections in Febrile Neutropenic Patients.- Susceptibility of Streptococci Isolated from Blood of Neutropenic Patients to 11 Antibiotics.- Emerging Antibiotic Resistance in bacterial Pathogens.- Cefepime Versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients.- Cefepime Versus Ceftazidime in the Empiric Treatment of Febrile Neutropenic Children with Malignancy.- Cefepime-Vancomycin Versus Ceftazidime-Vancomycin as Empiric Therapy in Febrile Neutropenic Patients.- Monotherapy with Meropenem Versus Combination Therapy with Ceftazidime Plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer.- Piperacillin plus Tazobactam Versus Ceftazidime plus Amikacin in Febrile Neutropenia: A Comparison in Terms of Cost and Efficacy.- Fungal Infection in Neutropenic Patients: Past Achivements and Future Problems.- The Pressure of Emerging Resistance in Fungal Diseases.- Liposomal Versus Conventional Amphotericin B for the Treatment of Fever of Unknown Origin in Neutropenic Patients: Results of two Randomized Trials in 204 Childrenand 134 Adults.- Pulmonary Infiltrate Etiology in Leukemic Patients with Fever.- Marrow Transplantation: Current Results and Effect of Immunoglobulin Prophylaxis.- The Role of Economic Evaluation in Assessing the Cost of Febrile Neutropenia.- Quality of life in Patients with Febrile Neutropenia.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
